Prudential Financial Inc. Has $46,000 Stake in OPKO Health, Inc. (NASDAQ:OPK)

Prudential Financial Inc. cut its stake in OPKO Health, Inc. (NASDAQ:OPK) by 69.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 31,356 shares of the biotechnology company’s stock after selling 69,700 shares during the period. Prudential Financial Inc.’s holdings in OPKO Health were worth $46,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Barclays PLC lifted its position in shares of OPKO Health by 154.5% in the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after purchasing an additional 329,870 shares in the last quarter. BNP Paribas Financial Markets lifted its position in OPKO Health by 736.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock worth $368,000 after buying an additional 217,450 shares in the last quarter. FMR LLC boosted its stake in shares of OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of OPKO Health in the 4th quarter valued at about $102,000. Finally, Essential Planning LLC. bought a new position in shares of OPKO Health in the 4th quarter valued at about $506,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Price Performance

Shares of NASDAQ OPK opened at $1.42 on Friday. OPKO Health, Inc. has a twelve month low of $1.15 and a twelve month high of $2.04. The company has a market cap of $950.24 million, a PE ratio of -7.45 and a beta of 1.78. The business’s 50 day moving average price is $1.69 and its two-hundred day moving average price is $1.58. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $183.60 million for the quarter, compared to analysts’ expectations of $155.42 million. On average, analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current year.

Insider Activity

In other news, CEO Phillip Md Et Al Frost bought 150,000 shares of the firm’s stock in a transaction dated Friday, January 17th. The shares were bought at an average price of $1.47 per share, with a total value of $220,500.00. Following the completion of the transaction, the chief executive officer now owns 213,186,477 shares of the company’s stock, valued at $313,384,121.19. This trade represents a 0.07 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have purchased 1,464,971 shares of company stock valued at $2,268,692 over the last ninety days. 49.69% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently commented on the company. Barrington Research reissued an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Wednesday, March 12th. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. Finally, HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of OPKO Health in a report on Monday, April 7th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.